Article online: phase 3 trial of #atezolizumab plus nab-#paclitaxel as first-line treatment for unresectable, locally advanced or metastatic #triplenegativebreastcancer—the IMpassion130 study
Just out📣 at IMpassion130 trial🔬 :atezolizumab +nab paclitaxel🧪as 1️⃣st line tx for unresectable, locally advanced or metastatic #TNBC #breastcancer . Suggests clinically meaningful OS benefit w/ atezolizumab➕nab-paclitaxel in PD-L1 +.
Atezolizumab + nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast ca. (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, ph 3 trial - The Lancet Oncology